secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protara Therapeutics, Inc. (TARA)
CIK:        0001359931
Form:       8-K
Filed at:   2023-01-30T23:59:59+00:00
Accession:  0001213900-23-005811
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Protara Therapeutics appoints Patrick Fabbio as CFO effective Jan 30, 2023
--------------------------------------------------------------------------

- Patrick Fabbio appointed CFO, replacing interim CFO Jesse Shefferman (CEO).
- Fabbio brings 30+ years life science finance experience; most recently President & CFO of Rafael Holdings.
- Compensation: $445k base salary, 45% target bonus, $25k signing bonus, 300k stock option (4-yr vest).
- Severance: without cause/good reason → 9 months base + 12 months target bonus + 9 months healthcare.
- On change-in-control termination within 12 months: 100% equity acceleration, 12 months base salary.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1359931/000121390023005811/0001213900-23-005811-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1359931/000121390023005811/ea172250-8k_protara.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-005811

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer